Related Experiment Videos
NN-414. Novo Nordisk
1Korea Research Institute of Chemical Technology, Medicinal Science Division, 100 Jang-dong, Yuseong-gu, 305-343 Daejeon-si, Korea. jkchoi@pado.krict.re.kr
Current Opinion in Investigational Drugs (London, England : 2000)
|June 18, 2003
Summary
Novo Nordisk is developing NN-414, a novel oral medication, to improve insulin release for diabetes treatment. Phase 1 trials assessed its efficacy in patients with type 1 and type 2 diabetes.
Area of Science:
- Pharmacology
- Endocrinology
- Diabetes Research
Background:
- Novo Nordisk is developing NN-414, an orally active compound.
- NN-414 acts as a beta-cell-selective regulator of insulin release.
- The drug is being investigated for potential use in treating type 1 and type 2 diabetes.
Purpose of the Study:
- To evaluate the efficacy of NN-414 in patients with diabetes.
- To assess the safety and tolerability of NN-414 during Phase 1 trials.
Main Methods:
- Phase 1 efficacy trials were conducted.
- Trials commenced by November 2000.
- Trials were ongoing in February 2002 and concluded by February 2003.
Main Results:
- Efficacy data from Phase 1 trials are available.
- Trial timelines indicate completion by February 2003.
Conclusions:
- NN-414 demonstrated potential as a treatment for type 1 and type 2 diabetes.
- Further development and trials are likely based on Phase 1 findings.